ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation

Treatment with 200 µmol per day of sulforaphane for 20 weeks was “feasible, safe,” and inhibited histone deacetylase (HDAC) function in a single-arm study of 20 patients who had non-castrate biochemical (PSA)-recurrence of prostate cancer despite surgery or radiation.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news